Skip to content
stoqly

Cooper Companies

COO Nasdaq Health Care Supplies Financials FY2016–FY2025

Cooper Companies' revenue rose 5.1% to $4.1 billion in fiscal 2025. Its operating margin was 16.7%, down from 18.1% a year earlier. Free cash flow was $434 million, up 50.5%. It paid out $290 million in dividends and buybacks, 67% of free cash flow. The diluted share count fell 0.2%.

Last close · Oct 23, 2026

$61.21

0.7%
Value it Compare
Revenue Total sales reported in the income statement.
$4.1B
5.1% vs prior year
Operating margin Operating income as a share of revenue.
16.7%
1.4 pts
Net income Profit after all expenses, interest and tax.
$375M
4.4%
Free cash flow Cash from operations minus capital spending.
$434M
50.5%
Return on capital After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
4.3%
0.4 pts
Market cap Last close times the latest diluted share count, so it is approximate.
$11.8B
Oct 23 close
P/E Last close divided by diluted earnings per share over the last four quarters.
21.0x
On $2.92 EPS (TTM)

About these figures. Share counts and per-share figures for earlier years are restated for a stock split (4-for-1), so every year is on today's share basis.

What Cooper Companies does

No business description yet.

Legal name
The Cooper Companies, Inc.
Fiscal year ends
October 31, 2025
Latest annual report
—
Accession · CIK
0001628280-25-055615
0000711404

Revenue and margins

Cooper Companies had $4.1B of revenue in fiscal 2025, up 5.1% on the year before.

Revenue
Revenue
Margins, % of revenue
Gross Operating Net FCF
Margins, % of revenue
Gross Operating Net FCF

Net income and earnings per share

From fiscal 2016 to 2025, diluted EPS grew 3.3% a year. Loss periods are shown in red.

Net income
Net income
Diluted EPS
Diluted EPS

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

Return on capital, equity and assets (annual)
Return on capital Return on equity Return on assets

Cash flow

Free cash flow was $434M in fiscal 2025, 10.6% of revenue. Cash from operations minus capital spending.

Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations Capital spending
Cash from operations vs capital spending
Cash from operations Capital spending

Dividends, buybacks and share count

Cooper Companies returned $290M to shareholders in fiscal 2025, 67% of free cash flow. The diluted share count fell 0.2%.

Dividends and buybacks
Dividends Buybacks
Dividends and buybacks
Dividends Buybacks
Diluted shares outstanding (annual)

Value Cooper Companies yourself

Change the assumptions and see what they imply per share. These are models, not forecasts or price targets — the answer depends entirely on what you put in.

Discounted cash flow

Value per share

—

Adds net cash of −$2.4B and divides by 200.0M diluted shares. Ten years of cash flows plus a terminal value, discounted to today.

Earnings multiple

Value per share

—

Reference multiples: today 21.0x · peers 40.7x · sector 28.4x.

Balance sheet

Cash, debt and the ratios that show how comfortably Cooper Companies can carry it.

Cash vs debt (incl. leases)
Cash Debt
Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments $95.9M$138M$121M$108M$111M
Debt incl. finance leases $1.4B$2.8B$2.6B$2.6B$2.5B
Net debt / EBITDA 1.6x3.1x2.7x2.3x2.3x
Debt / equity 0.2x0.4x0.3x0.3x0.3x
Interest coverage 21.9x8.9x5.1x6.2x6.8x
Current ratio 2.0x1.2x1.8x1.9x1.9x
Quick ratio 1.2x0.7x1.0x1.1x1.1x
Total assets $9.6B$11.5B$11.7B$12.3B$12.4B
Total liabilities $2.7B$4.3B$4.1B$4.2B$4.2B
Shareholders' equity $6.9B$7.2B$7.6B$8.1B$8.2B
Net debt (− = net cash) $1.3B$2.6B$2.4B$2.5B$2.4B

Insider trades

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.

Bought, 12 months

$3.2M

7 insiders

Sold, 12 months

$0.0M

0 insiders

Of sales under plans

—

$0.0M

DateInsiderTradeSharesPriceValueFiling
Sep 16, 2026 Lawrence Erik KurziusDirector Bought 10,000 $54.93 $0.5M Form 4
Sep 14, 2026 Lawrence Erik KurziusDirector Bought 10,000 $53.92 $0.5M Form 4
Sep 14, 2026 Walter M Rosebrough JrDirector Bought 3,000 $54.29 $0.2M Form 4
Sep 11, 2026 Paul A KeelDirector Bought 4,701 $53.18 $0.2M Form 4
Sep 11, 2026 Walter M Rosebrough JrDirector Bought 7,000 $54.11 $0.4M Form 4
Dec 22, 2025 Cynthia L LuccheseDirector Bought 1,784 $84.06 $0.1M Form 4
Dec 18, 2025 Maria RivasDirector Bought 1,000 $82.13 $0.1M Form 4
Dec 17, 2025 Lawrence Erik KurziusDirector Bought 2,000 $82.50 $0.2M Form 4
Dec 16, 2025 Albert G White IIIPresident & CEO, Director Bought 10,000 $80.80 $0.8M Form 4
Dec 16, 2025 Holly R SheffieldPresident, Csi Bought 1,230 $80.75 $0.1M Form 4

Piotroski F-score

Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.

TestFY23FY24FY25
Net income is positive ✓ ✓ ✓
Cash from operations is positive ✓ ✓ ✓
Return on assets rose ✕ ✓ ✕
Cash from operations exceeds net income ✓ ✓ ✓
Debt fell relative to assets ✓ ✓ ✓
Current ratio rose ✓ ✓ ✕
Share count didn't rise ✕ ✕ ✓
Gross margin rose ✓ ✓ ✕
Revenue rose relative to assets ✕ ✓ ✕
F-score 6 / 98 / 95 / 9
Accruals ratio −2.7%−2.6%−3.4%
Altman Z'' 4.574.814.99

Similar companies

Each company's latest fiscal year. Fiscal years end in different months, so periods don't line up exactly.

CompanyMarket capGrowthOp. marginFCF marginROICP/EF-score
Cooper Companies COO $11.8B 5.1% 16.7% 10.6% 4.3% 21.0x 5
Align Technology ALGN $11.0B 0.9% 13.5% 12.2% 13.3% 26.9x 5 Compare →
Dentsply Sirona XRAY $1.9B −3.0% −11.5% 2.8% −9.9% — 6 Compare →
West Pharmaceutical Services WST $28.0B 6.3% 19.0% 15.3% 18.7% 50.2x 9 Compare →
Envista NVST $3.9B 8.3% 8.0% 8.5% 3.2% 40.7x 7 Compare →

10 years of figures

US$ millions unless stated. Hover a ratio's name for its definition.

Download CSV
Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue $2.0B $2.1B $2.5B $2.7B $2.4B $2.9B $3.3B $3.6B $3.9B $4.1B
Gross profit $1.2B $1.4B $1.6B $1.8B $1.5B $2.0B $2.1B $2.4B $2.6B $2.7B
Research and development $65.4M $69.2M $84.8M $86.7M $93.3M $92.7M $110M $137M $155M $172M
Operating income $324M $429M $403M $547M $312M $506M $508M $533M $706M $683M
Interest expense $26.2M $33.4M $82.7M $68.0M $36.8M $23.1M $57.3M $105M $114M $100M
Pretax income $296M $394M $332M $477M $267M $492M $475M $413M $582M $567M
Income tax $20.7M $21.1M $192M $10.7M $28.1M −$2.5B $89.5M $119M $190M $192M
Net income $274M $373M $140M $467M $238M $2.9B $386M $294M $392M $375M
Diluted EPS $1.40 $1.88 $0.70 $2.33 $1.20 $14.79 $1.94 $1.48 $1.96 $1.87
Diluted shares 0.20B 0.20B 0.20B 0.20B 0.20B 0.20B 0.20B 0.20B 0.20B 0.20B
Cash flow
Cash from operations $510M $594M $669M $713M $487M $739M $692M $608M $709M $796M
Capital expenditure $153M $127M $194M $292M $310M $214M $242M $393M $421M $362M
Free cash flow $357M $466M $475M $421M $176M $524M $450M $215M $288M $434M
Depreciation and amortization $198M $188M $275M $281M $287M $309M $346M $368M $375M $377M
Stock-based compensation $29.9M $37.2M $43.2M $35.1M $37.6M $43.8M $54.2M $62.1M $75.1M $70.5M
Acquisitions $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M
Share buybacks $0.0M $55.0M $0.0M $156M $47.8M $24.8M $78.5M $0.0M $0.0M $290M
Dividends paid $2.9M $2.9M $2.9M $3.0M $3.0M $3.0M $3.0M $3.0M $0.0M $0.0M
Dividends and buybacks $2.9M $57.9M $2.9M $159M $50.8M $27.8M $81.5M $3.0M $0.0M $290M
Balance sheet
Cash and short-term investments $101M $88.8M $77.7M $89.0M $116M $95.9M $138M $121M $108M $111M
Total debt $1.5B $1.2B $2.0B $1.3B $1.4B $1.4B $2.7B $2.6B $2.6B $2.5B
Finance lease liabilities $0.0M $0.0M $0.0M $0.0M $2.4M $2.0M $20.6M $4.4M $3.5M $2.5M
Current assets $937M $953M $1.1B $1.2B $1.3B $1.5B $1.5B $1.7B $2.0B $2.1B
Current liabilities $543M $396M $537M $1.1B $1.0B $732M $1.3B $969M $1.0B $1.1B
Inventory $418M $454M $469M $507M $570M $586M $629M $736M $803M $846M
Property and equipment, net $878M $910M $976M $1.1B $1.3B $1.3B $1.4B $1.6B $1.9B $2.1B
Total assets $4.5B $4.9B $6.1B $6.3B $6.7B $9.6B $11.5B $11.7B $12.3B $12.4B
Total liabilities $1.8B $1.7B $2.8B $2.6B $2.9B $2.7B $4.3B $4.1B $4.2B $4.2B
Shareholders' equity $2.7B $3.2B $3.3B $3.6B $3.8B $6.9B $7.2B $7.6B $8.1B $8.2B
Margins
Gross margin 59.7% 63.9% 64.5% 66.2% 63.1% 66.9% 64.7% 65.6% 66.6% 65.5%
Operating margin 16.5% 20.1% 15.9% 20.6% 12.8% 17.3% 15.3% 14.8% 18.1% 16.7%
EBITDA margin 26.6% 28.9% 26.8% 31.2% 24.6% 27.9% 25.8% 25.1% 27.8% 25.9%
Net margin 13.9% 17.4% 5.5% 17.6% 9.8% 100.8% 11.7% 8.2% 10.1% 9.2%
FCF margin 18.2% 21.8% 18.8% 15.9% 7.3% 17.9% 13.6% 6.0% 7.4% 10.6%
Returns
Return on capital 7.4% 9.7% 4.2% 10.6% 5.6% 7.6% 4.6% 3.8% 4.6% 4.3%
Return on capital employed 8.3% 10.2% 8.0% 10.2% 5.7% 6.9% 5.3% 5.1% 6.4% 6.1%
Return on equity 10.2% 12.7% 4.3% 13.5% 6.4% 54.7% 5.5% 4.0% 5.0% 4.6%
Return on assets 6.1% 8.0% 2.6% 7.5% 3.7% 36.0% 3.7% 2.5% 3.3% 3.0%
Growth
Revenue growth 9.4% 8.8% 18.4% 4.8% −8.4% 20.2% 13.2% 8.6% 8.4% 5.1%
Net income growth 34.6% 36.1% −62.5% 233.6% −48.9% 1,135.2% −86.9% −23.7% 33.3% −4.4%
EPS growth 35.0% 34.5% −62.6% 232.0% −48.5% 1,129.9% −86.9% −23.7% 32.4% −4.6%
FCF growth 141.4% 30.6% 1.9% −11.4% −58.2% 197.5% −14.1% −52.3% 34.0% 50.5%
Share count change −0.4% 1.2% 0.2% 0.6% −0.8% 0.4% −0.2% 0.3% 0.6% −0.2%
Financial health
Net debt / EBITDA 2.8x 1.8x 2.9x 1.4x 2.1x 1.6x 3.1x 2.7x 2.3x 2.3x
Debt / equity 0.6x 0.4x 0.6x 0.4x 0.4x 0.2x 0.4x 0.3x 0.3x 0.3x
Interest coverage 12.4x 12.9x 4.9x 8.0x 8.5x 21.9x 8.9x 5.1x 6.2x 6.8x
Current ratio 1.7x 2.4x 2.0x 1.1x 1.3x 2.0x 1.2x 1.8x 1.9x 1.9x
Quick ratio 1.0x 1.3x 1.2x 0.6x 0.7x 1.2x 0.7x 1.0x 1.1x 1.1x
Capital allocation
Capex / revenue 7.8% 6.0% 7.6% 11.0% 12.8% 7.3% 7.3% 10.9% 10.8% 8.9%
Stock comp / revenue 1.5% 1.7% 1.7% 1.3% 1.6% 1.5% 1.6% 1.7% 1.9% 1.7%
Payouts / FCF 0.8% 12.4% 0.6% 37.8% 28.8% 5.3% 18.1% 1.4% 0.0% 66.9%
Quality scores
Piotroski F-score 8.0 8.0 5.0 6.0 5.0 7.0 4.0 6.0 8.0 5.0
Altman Z'' 4.1 5.0 3.7 3.7 3.5 5.7 4.1 4.6 4.8 5.0
Accruals ratio −5.3% −4.7% −9.6% −4.0% −3.8% 27.0% −2.9% −2.7% −2.6% −3.4%

Source: SEC EDGAR XBRL filings (CIK 0000711404). Data updated October 10, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.

↑ ↓ to move · ↵ to open